May 2024 in “European Journal of Immunology” This review discusses the potential of targeting Coenzyme A metabolism to restore metabolic balance, reduce chronic inflammation, and enhance immune function, particularly by modulating Vitamin B5 pathways involved in Th17-mediated inflammation and CD8-dependent anti-tumor immunity.
In this study, the combined treatment of ursolic acid and resveratrol was evaluated for its effects on skin tumor promotion in female FVB mice. The combination was applied topically before TPA treatment and was found to significantly inhibit TPA-induced epidermal hyperproliferation, signaling pathways, and skin inflammation more effectively than either compound alone. Key signaling pathways affected included EGFR, STAT3, and NF-κB, among others. The combination also increased tumor suppressor levels and reduced proinflammatory cytokine expression. Overall, the combined treatment resulted in a greater reduction in tumor multiplicity and size, highlighting its potential as a more effective strategy for inhibiting skin tumor promotion compared to individual treatments.
In this study, the combined treatment of ursolic acid and resveratrol was evaluated for its inhibitory effects on skin tumor promotion in female FVB mice. The combination was applied topically before TPA treatment and was found to significantly inhibit TPA-induced epidermal hyperproliferation, signaling pathways, and skin inflammation more effectively than either compound alone. Key signaling pathways affected included EGFR, STAT3, and NF-κB, among others. The combination also increased tumor suppressor levels and reduced proinflammatory cytokine expression. Overall, the combined treatment resulted in a greater reduction in tumor multiplicity and size, highlighting its potential as a more effective strategy for preventing skin tumor promotion compared to individual treatments.
September 2002 in “Oncology Times” This study presented at the ASCO Annual Meeting reported that the epidermal growth factor receptor antibody ABX-EGF showed preliminary efficacy in renal cell cancer patients, with tolerable side effects, while bortezomib demonstrated clinical benefit in a significant proportion of multiple myeloma patients.
November 2025 in “Eurasian journal of applied biotechnology” In this study, combining L-cysteine and N-acetylcysteine with MET inhibition enhanced cytotoxicity in cancer cell lines by sensitizing them to MET inhibition through redox stabilization, suggesting a promising approach for improving MET-targeted cancer therapies without additional oxidative or chemotherapeutic stress.
